Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06055608 · ClinicalTrials.gov registry record · Phase 2
Advancing Transplantation Outcomes in Children
A Phase 2 study of Kidney Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06055608 is a Phase 2 study of Kidney Transplant that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 200 participants, below the 1,892-participant average among 30 other Kidney Transplant trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT06055608, a Phase 2 study of Kidney Transplant, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a pediatric kidney transplant study comparing the safety and efficacy of an immunosuppressive regimen of belatacept and sirolimus to tacrolimus and Mycophenolate Mofetil (MMF). Two hundred participants will be randomized (1:1) to one of two groups within 24 hours following the transplant procedure. The duration of the study from time of transplant to the primary endpoint is 12-24 months.
Conditions Studied
Interventions
- DRUG Sirolimus
- DRUG Mycophenolate Mofetil
- BIOLOGICAL Belatacept
- DRUG Tacrolimus (Group1)
- DRUG Anti-Thymocyte Globulin (ATG)
Study Locations (20)
California
- Children's Hospital of Los Angeles (Site #: 71036) - Los Angeles
- Cedars-Sinai Medical Center (Site #: 71026) - Los Angeles
- Mattel Children's Hospital, UCLA (Site #: 71012) - Los Angeles
- UCSD Rady Children's Hospital (Site #: 71037) - San Diego
Pennsylvania
- Children's Hospital of Philadelphia (Site #: 71091) - Philadelphia
- UPMC Children's Hospital of Pittsburgh (Site #: 71008) - Pittsburgh
Alabama
- University of Alabama at Birmingham (Site # 71038) - Birmingham
Colorado
- Children's Hospital of Colorado (Site #: 71019) - Aurora
Delaware
- Nemours Children's Health (Site #: 71042) - Wilmington
District of Columbia
- Children's National Medical Center (Site #: 71039) - Washington D.C.
Illinois
- Ann and Robert H. Lurie Children's Hospital of Chicago (Site #: 71016) - Chicago
Maryland
- Johns Hopkins Children's Center (Site #: 71025) - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-05-22 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06055608
The ClinicalTrials.gov registry entry for NCT06055608 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,892-participant average among 30 other Kidney Transplant trials with a reported enrollment target (89% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Transplant appearing as the primary indexed condition, and to 5 interventions - of which Sirolimus is the first listed.
NCT06055608 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Pennsylvania, Alabama.
Frequently Asked Questions
What is clinical trial NCT06055608 about?
NCT06055608 is a clinical study titled "Advancing Transplantation Outcomes in Children". This is a pediatric kidney transplant study comparing the safety and efficacy of an immunosuppressive regimen of belatacept and sirolimus to tacrolimus and Mycophenolate Mofetil (MMF). Two hundred participants will be randomized (1:1) to one of two groups within 24 hours following the transplant pro...
What is the current status of trial NCT06055608?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2024-05-22. Estimated completion is 2028-06-30.
What conditions does trial NCT06055608 study?
This clinical trial studies the following conditions: Kidney Transplant.
What interventions are being tested in trial NCT06055608?
The interventions under investigation include: Sirolimus (DRUG), Mycophenolate Mofetil (DRUG), Belatacept (BIOLOGICAL), Tacrolimus (Group1) (DRUG), Anti-Thymocyte Globulin (ATG) (DRUG).
Who is sponsoring clinical trial NCT06055608?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06055608 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation
RECRUITING · Phase 2
-
Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)
RECRUITING · Phase 2
-
Sotagliflozin Safety and Tolerability Among Renal Transplant Recipients
COMPLETED · Phase 2
-
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
COMPLETED · Phase 2
-
COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study
COMPLETED · Phase 2
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.